海尔生物
(688139)
| 流通市值：118.47亿 | | | 总市值：118.47亿 |
| 流通股本：3.18亿 | | | 总股本：3.18亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 686,909,061.52 | 2,280,896,019.23 | 1,826,339,651.43 | 1,270,455,870.9 |
| 营业收入 | 686,909,061.52 | 2,280,896,019.23 | 1,826,339,651.43 | 1,270,455,870.9 |
| 二、营业总成本 | 538,737,974.7 | 1,966,937,346.46 | 1,528,552,037.64 | 1,034,950,299.72 |
| 营业成本 | 346,205,232.18 | 1,125,977,841.74 | 897,464,793.55 | 613,796,745.2 |
| 税金及附加 | 5,757,824.8 | 20,814,451.67 | 15,618,579.09 | 11,684,386.05 |
| 销售费用 | 80,476,077.76 | 339,573,972.29 | 251,803,065 | 168,807,126.2 |
| 管理费用 | 41,044,822.78 | 183,467,514.04 | 135,906,685.33 | 93,716,330.74 |
| 研发费用 | 77,257,984.27 | 320,636,061.79 | 242,651,271.93 | 157,574,507.09 |
| 财务费用 | -12,003,967.09 | -23,532,495.07 | -14,892,357.26 | -10,628,795.56 |
| 其中:利息费用 | 842,633.79 | 3,511,618.34 | 2,845,834.97 | 1,877,762.2 |
| 其中:利息收入 | 13,038,215.13 | 35,609,318.83 | 23,938,719.46 | 14,578,931.76 |
| 加:公允价值变动收益 | 334,520 | 2,055,633.22 | -4,125,990.78 | 1,459,949.22 |
| 加:投资收益 | 3,291,655.49 | 83,033,401.63 | 73,352,937.38 | 58,134,146.01 |
| 资产处置收益 | -81,512.41 | -1,599,128.48 | -2,062,769.54 | -2,062,769.54 |
| 资产减值损失(新) | -12,496.58 | -1,642,752.84 | -1,459,756.76 | -1,520,953.03 |
| 信用减值损失(新) | -6,728,018.99 | -2,418,299.47 | -993,675.42 | -431,240.09 |
| 其他收益 | 9,301,428.65 | 45,013,812.56 | 32,681,352.71 | 20,940,129.35 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 154,276,662.98 | 438,401,339.39 | 395,179,711.38 | 312,024,833.1 |
| 加:营业外收入 | 446,140.86 | 3,341,881.01 | 2,512,599.46 | 1,309,461 |
| 减:营业外支出 | 21,412.15 | 7,252,010.97 | 6,069,846.67 | 6,069,189.79 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 154,701,391.69 | 434,491,209.43 | 391,622,464.17 | 307,265,104.31 |
| 减:所得税费用 | 12,849,152.72 | 22,432,550.67 | 25,976,619 | 23,053,475.27 |
| 六、净利润 | 141,852,238.97 | 412,058,658.76 | 365,645,845.17 | 284,211,629.04 |
| 持续经营净利润 | 141,852,238.97 | 412,058,658.76 | 365,645,845.17 | 284,211,629.04 |
| 归属于母公司股东的净利润 | 137,614,697.49 | 406,073,643.93 | 357,201,281.16 | 278,462,841.61 |
| 少数股东损益 | 4,237,541.48 | 5,985,014.83 | 8,444,564.01 | 5,748,787.43 |
| (一)基本每股收益 | 0.44 | 1.28 | 1.13 | 0.88 |
| (二)稀释每股收益 | 0.44 | 1.28 | 1.13 | 0.88 |
| 八、其他综合收益 | 12,754.54 | -43,521,492.11 | -30,515,814.23 | -29,978,428.73 |
| 归属于母公司股东的其他综合收益 | 12,754.54 | -43,521,492.11 | -30,515,814.23 | -29,978,428.73 |
| 九、综合收益总额 | 141,864,993.51 | 368,537,166.65 | 335,130,030.94 | 254,233,200.31 |
| 归属于母公司股东的综合收益总额 | 137,627,452.03 | 362,552,151.82 | 326,685,466.93 | 248,484,412.88 |
| 归属于少数股东的综合收益总额 | 4,237,541.48 | 5,985,014.83 | 8,444,564.01 | 5,748,787.43 |
| 公告日期 | 2024-04-26 | 2024-03-28 | 2023-10-27 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |